北京
分享至
贝达药业(300558.SZ)发布公告，公司合作伙伴EyePoint Pharmaceuticals, Inc.(NASDAQ：EYPT，以下简称“EyePoint”)公布了其在研伏罗尼布眼科制剂EYP-1901玻璃体内植入剂(DURAVYU™，以下简称“DURAVYU”)治疗湿性年龄相关性黄斑变性(以下简称“wAMD”)开展的两项关键Ⅲ期临床试验中的首项试验LUGANO的数据。
本文源自：金融界AI电报
特别声明：以上内容(如有图片或视频亦包括在内)为自媒体平台“网易号”用户上传并发布，本平台仅提供信息存储服务。
Notice: The content above (including the pictures and videos if any) is uploaded and posted by a user of NetEase Hao, which is a social media platform and only provides information storage services.
